More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wave of Debt Payments Facing US Government
- Why Amazon Rules Retail
- HP Comes in As Expected; Is It Time to Buy?
- JAL Slides to Record Low on Bankruptcy Jitters
- Paul: Audit the Fed
- Hewlett-Packard Profit Rises, Matches Guidance
- Prepare For Large Decline In Stocks, Next Year?
- The Social Media Gaming Threat
- Holiday Travel Outlook
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Obama says Boosting US Jobs is Top Priority
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Earnings Rise, Match Guidance
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
] is quoting me in a letter to shareholders. AMLN is engaged in an escalating proxy fight with billionaire activist investor Carl Icahn and another big investment firm, Eastbourne. The challengers want to install their own people on the Board of Directors and to presumably sell the company.
Amylin says maintaining the status quo and staying the course is the way to go. And the letter Kliff was telling me about is just the latest salvo.
As the May 27th shareholder meeting and the vote get closer the rhetoric is heating up.
For example, in the new letter Amylin says (all in caps and boldface type), "DO NOT BE MISLED BY ICAHN AND EASTBOURNE. THEIR ONLY PLAN IS TO SELL THE COMPANY AT THE WRONG TIME.". By the way, I think it's worth noting that AMLN put "at the wrong time" in there.
Anyway, while on the one hand I guess I'm flattered, on the other I'm a bit uncomfortable. I'm a reporter. I just cover the story. I don't want to become part of it. Ever.
I want to make absolutely clear to anyone who might try to misinterpret the use of my name in the SEC filing that the quote does not reflect my opinion of Amylin or Byetta or its prospects as a once-a-week injection for diabetes. It was lifted from my on-air CNBC coverage last week of the company's filing for FDA approval of once-a-week Byetta. Amylin is partners with Eli Lilly [LLY
Loading...
()
] and Alkermes [ALKS
Loading...
()
] on the product.
If you read the quote you'll notice that I source the projections for once-a-week Byetta's sales potential to analysts. It is not my analysis or my opinion. In journalism it's called attribution.
Interestingly, in a subsequent press release issued Monday morning about the new SEC filing containing the letter to shareholders there's now a supporting quote, in addition to mine, from an actual analyst.
I certainly don't object to being quoted. After all, that's what I do...quote people. I simply don't want Amylin's use of my quote to be misconstrued by anyone that it in any way means I'm taking sides here. I am not. I would never.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes